VPT:CC - Ventripoint Announces Collaboration with Ascend Cardiovascular
(TheNewswire)
Toronto, Ontario – The Newswire –August 10, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is thrilled to announce that Ventripoint andAscend Cardiovascular, a leading provider of cardiovascular ITsolutions, have solidified a strategic collaboration. The twocompanies have signed a letter of intent to explore joint research anddevelopment initiatives, knowledge sharing, and combining efforts tobring innovative AI-based solutions to the market.
Ascend Cardiovascular has over two decades ofexperience in cardiovascular IT and is an expert in cardiologyworkflow. Ascend’s clinical reporting, device interfaces, andanalytics are used daily by some of the top institutions and hospitalsystems in North America.
The teamwork between Ventripoint and Ascend leveragesthe strengths and expertise of both Ascend and Ventripoint to enhancecardiovascular diagnostics and improve patient care. By combining thecapabilities of Ventripoint and Ascend, both companies aim to developand integrate solutions to improve diagnostic accuracy, streamlineworkflows, and enhance patient experience. Ascend intends to resellVentripoint products developed through this partnership and integratedwith Ascend’s cardiovascular IT platform.
“This collaboration with Ascend Cardiovascular ispart of Ventripoint’s mission to elevate cardiac care by providingbetter tools for clinicians. We are excited about what the twocompanies can accomplish by joining efforts,” stated Dr. AlviraMacanovic, President & CEO of Ventripoint.
This coordination will include exploring jointresearch and development initiatives aimed at enhancing existingcardiovascular diagnostic technologies and identifying newopportunities. This may include jointprojects, knowledge sharing, and collaborative efforts to seekregulatory approvals and commercialize new products or servicesincluding, where applicable, co-marketing and sales supportactivities
"Ascend is on a mission to provide a fullyintegrated, best-of-breed cardiovascular workflow solution to itscustomers. Integration with Ventripoint's innovative solution for 3Dvisualization will provide tremendous value to pediatric and adultechocardiographers in the care of their most complex patients,"stated Dr. Jeff Soble, CEO of Ascend Cardiovascular.
Both Ventripoint and Ascend are excited about thepotential impact of this collaboration within the field ofcardiovascular diagnostics. Ascend brings their clinical and industryknowledge, along with its proprietary structured reporting, and itsechocardiogram DICOM viewer to the collaboration. Ventripoint bringsits proprietary AI-based diagnostic technologies, researchcapabilities, and technical expertise in cardiovascular imaging andanalysis. By combining the unique expertise and resources of bothcompanies, new solutions can be made that address existing challengeswithin the industry.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada. Learn more: www.ventripoint.com.
About Ascend Cardiovascular
ASCEND Cardiovascular is a leader in innovatingcardiovascular solutions that empower the provider community toimprove cardiovascular care. Designed with openness in mind, oursolutions integrate with EHRs, medical devices, and other systems todeliver seamless workflows that span procedure types and modalities. Acomplete cardiovascular solution, ASCEND provides structuredreporting, image visualization, collaboration, and analytics thatimprove efficiency, outcomes, and ROI. With decades of experience anda practicing cardiologist at our helm, the ASCEND team bringsunparalleled “know how” in cardiology workflow, collaboration, andIT offering limitless opportunities to improve clinical, operational,and quality performance. Learn more: www.ascendcv.com .
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.